HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Pre-market Approval Resurfaces From Blumenthal, Durbin

This article was originally published in The Tan Sheet

Executive Summary

Sen. Blumenthal plans a floor amendment to the FY17 National Defense Authorization Act to require third-party verification for supplements sold at retail establishments on US military posts. The amendment likely would have support from Sen. Durbin, who joined Blumenthal in introducing a similar amendment in 2015.

You may also be interested in...



Legislating CBD As Lawful Supplement Ingredient: A Threatening Precedent For US Industry?

Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act introduced in House isn’t supported by key Democrat and Republican leaders in both chambers partly because of regulatory precedent it proposes, says lobbyist NPA Steve Northrup.

PharmaTech Recalls Highlight Supplement GMP Diligence For Marketers – CRN

PharmaTech customers recall liquid supplements, including products indicated for children, after CDC informs FDA that an antibiotic-resistant pathogen was found in a PharmaTech Rx drug. CRN says the recall should remind supplement firms about tracking supply chains and auditing contract manufacturers.

Canada Tilts At Unneeded Fixes In Self-Care Product Regulation Overhaul – Industry

Health Canada says its planned overhaul will not scrap the current natural health product framework, but industry is skeptical. In a Council for Responsible Nutrition webinar, an industry consultant says marketers of OTC drugs, supplements and cosmetics are discussing the proposal's negative implications with the agency.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel